![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Cytos, Medarex Expand Collaboration for New Drug Targets
Cytos, Medarex Expand Collaboration for New Drug Targets
April 1, 2005
Cytos Biotechnology AG and Medarex, Inc. announced that the two companies have expanded the scope of their collaborative research, development and license agreement for new drug targets. The first agreement between the companies was announced in November 2002 and focused on drug targets for immunological diseases. This new agreement expands the collaboration scope and will include drug targets discovered in other disease areas of interest.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-01-2005/0003297280&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct